L-M Tseng

428 total citations
20 papers, 223 citations indexed

About

L-M Tseng is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, L-M Tseng has authored 20 papers receiving a total of 223 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in L-M Tseng's work include HER2/EGFR in Cancer Research (9 papers), Cancer Treatment and Pharmacology (7 papers) and Advanced Breast Cancer Therapies (6 papers). L-M Tseng is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Cancer Treatment and Pharmacology (7 papers) and Advanced Breast Cancer Therapies (6 papers). L-M Tseng collaborates with scholars based in Taiwan, United States and South Korea. L-M Tseng's co-authors include Luca Gianni, Tania Szado, Y-H Im, MC Liu, L Roman, Tadeusz Pieńkowski, Y.H. Park, Javier Cortés, S-A. Im and Jillian Cathcart and has published in prestigious journals such as Cancer Research, Annals of Oncology and Value in Health.

In The Last Decade

L-M Tseng

18 papers receiving 220 citations

Peers

Countries citing papers authored by L-M Tseng

Since Specialization

Citations

This map shows the geographic impact of L-M Tseng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L-M Tseng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L-M Tseng more than expected).

Fields of papers citing papers by L-M Tseng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L-M Tseng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L-M Tseng. The network helps show where L-M Tseng may publish in the future.

Co-authorship network of co-authors of L-M Tseng

This figure shows the co-authorship network connecting the top 25 collaborators of L-M Tseng. A scholar is included among the top collaborators of L-M Tseng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L-M Tseng. L-M Tseng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	555MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment (tx) for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Final results from the phase Ib/II BEGONIA study 2025 ·Annals of Oncology ·Peter Schmid, Hao‐Chien Wang, (unknown), Y.H. Park, X. Cynthia, (unknown), S.C. Chen, (unknown), Catherine Prady, L-M Tseng, Jamil Asselah, Piotr J. Wysocki, Simon Lord, (unknown), Ross Stewart, (unknown), (unknown), S-A. Im	1
2	A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases 2024 ·Annals of Oncology ·Fabrice André, Javier Cortés, (unknown), (unknown), Wěi Li, Y.H. Park, (unknown), S.-B. Kim, Toshinari Yamashita, José Luiz Pedrini, (unknown), L-M Tseng, (unknown), Ian E. Krop, (unknown), Kristen M. Tecson, Shahid Ashfaque, Anton Egorov, (unknown)	15
3	LBA5 Capivasertib (C) + fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Phase III CAPItello-291 trial Chinese cohort 2023 ·Annals of Oncology ·Xingjiang Hu, Qingfu Zhang, Tao Sun, Hua Xiong, (unknown), Yanling Teng, Yen‐Shen Lu, L-M Tseng, (unknown), Han Li, Da Pang, S.C. Chen, (unknown), Ou Jiang, Jianliu Wang, Xianghua Wu, (unknown), Jiang Lin, Xin Zeng, Nicholas C. Turner	0
4	16P Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment 2023 ·Annals of Oncology ·(unknown), Yoland Antill, (unknown), Carlos Shimizu, (unknown), L-M Tseng, (unknown), (unknown), (unknown), (unknown), David S. Hsu	0
5	377O A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03 2023 ·Annals of Oncology ·(unknown), Shanu Modi, Wěi Li, Y.H. Park, Wei‐Pang Chung, S-B. Kim, Javier Cortés, Toshinari Yamashita, José Luiz Pedrini, S-A. Im, L-M Tseng, Nadia Harbeck, (unknown), G. Curigliano, E. Mathias, Jillian Cathcart, (unknown), Shahid Ashfaque, Anton Egorov, Fabrice André	24
6	LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study 2021 ·Annals of Oncology ·Javier Cortés, S-B. Kim, (unknown), S-A. Im, Y.H. Park, Roberto Hegg, (unknown), L-M Tseng, Vanessa Petry, (unknown), Hiroji Iwata, E.P. Hamilton, Giuseppe Curigliano, Binghe Xu, (unknown), (unknown), Jillian Cathcart, Emarjola Bako, Sunil Verma, Sara A. Hurvitz	73
7	Abstract P3-05-19: Regorafenib induces immunogenic cell death via p-stat3 inhibition in triple negative breast cancer cells 2018 ·Cancer Research ·Chia‐Yang Liu, (unknown), (unknown), Ji‐Long Chen, Pei‐Yi Chu, (unknown), Wang Wl, L-M Tseng	2
8	Abstract P5-21-13: Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial 2018 ·Cancer Research ·S-A. Im, Binghe Xu, (unknown), Mark E. Robson, Quchang Ouyang, (unknown), Hiroji Iwata, YH Park, (unknown), L-M Tseng, Carsten Goessl, Wencheng Wu, Sarah Runswick, Norikazu Masuda	1
9	Kynurenine-3-monooxygenase (KMO) protein promotes triple negative breast cancer progression 2017 ·Annals of Oncology ·Chia‐Yang Liu, (unknown), Chi‐Hang Lee, Wang Wl, (unknown), L-M Tseng	5
10	Multicenter phase 2 trial of varlitinib versus lapatinib in combination with capecitabine in patients with HER2+ metastatic breast cancer (MBC) who failed prior trastuzumab therapy 2017 ·Annals of Oncology ·(unknown), (unknown), (unknown), (unknown), CL Liu, Arlene Chan, (unknown), L-M Tseng, Wen Yee Chay, Louis WC Chow, (unknown), (unknown), Hao‐Chien Wang, (unknown), (unknown), Joanne Chiu, Bridget A. Robinson, Bertil Lindmark, (unknown), (unknown)	5
11	Abstract P2-08-25: Impact of kynurenine 3-monooxygenase expression on outcome in patients with triple-negative breast cancer undergone primary treatments 2016 ·Cancer Research ·(unknown), Pei‐Yi Chu, Wang Wl, Chia‐Yang Liu, L-M Tseng	1
12	Abstract P4-13-27: A phase Ib dose de-escalation study of combined tamoxifen and goserelin acetate with alpelisib (BYL719) or buparlisib (BKM120) in premenopausal patients with HR+/HER2– locally advanced or metastatic breast cancer 2016 ·Cancer Research ·Yen‐Shen Lu, Jungsil Ro, L-M Tseng, (unknown), Imjai Chitapanarux, (unknown), (unknown), (unknown), YH Park	4
13	Abstract P2-16-02: Bevacizumab, etoposide, and cisplatin (BEEP) is highly effective in brain metastases of HER2 positive breast cancer progressing from whole brain radiotherapy - Subgroup analysis of a multi-center phase II study 2013 ·Cancer Research ·Yen‐Shen Lu, (unknown), Ching‐Hsiung Lin, (unknown), L-M Tseng, (unknown), Bang‐Bin Chen, (unknown), (unknown), (unknown), (unknown), Chiun‐Sheng Huang, Ann‐Lii Cheng	1
14	Abstract OT1-1-17: LUX-Breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab and/or lapatinib* 2012 ·Cancer Research ·Tamas Hickish, (unknown), Minish Jain, Chiun‐Sheng Huang, Н. В. Коваленко, (unknown), (unknown), Martina Uttenreuther‐Fischer, L-M Tseng, (unknown)	3
15	S5-1: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Biomarker Analyses of a 4-Arm Randomized Phase II Study (NeoSphere) in Patients (pts) with HER2−Positive Breast Cancer (BC). 2011 ·Cancer Research ·Luca Gianni, Giampaolo Bianchini, Astrid Kiermaier, Giulia Bianchi, Y-H Im, Tadeusz Pieńkowski, L Roman, MC Liu, L-M Tseng, Jithendra Ratnayake, Tania Szado, (unknown), Pinuccia Valagussa	33
16	Abstract S3-2: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ('NeoSphere') 2010 ·Cancer Research ·Luca Gianni, Tadeusz Pieńkowski, Y-H Im, L Roman, L-M Tseng, MC Liu, (unknown), Semiglazov Vf, Tania Szado, G. Ross	48
17	Abstract PD07-02: βIII Tubulin Expression by Immunohistochemistry (IHC) and mRNA in a Randomized Phase 2 Neoadjuvant Breast Cancer (BC) Study of Ixabepilone (ixa) Compared to Paclitaxel (pac) 2010 ·Cancer Research ·Christine E. Horak, Lajos Pusztai, Boyd Mudenda, (unknown), Ovidiu C. Trifan, Cristina Saura, L-M Tseng, Siu‐Ki Chan, (unknown), (unknown)	1
18	Abstract PD07-01: Phase 2 Study of Ixabepilone Versus Paclitaxel as Neoadjuvant Therapy for Early Stage Breast Cancer with Comparative Biomarker Analysis 2010 ·Cancer Research ·Cristina Saura, L-M Tseng, Sherry Kit Wa Chan, (unknown), Mario Campone, (unknown), (unknown), Boyd Mudenda, Christine E. Horak, (unknown), Lajos Pusztai	1
19	PCN16 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB FOR HER-2 POSITIVE EARLY BREAST CANCER IN TAIWAN 2007 ·Value in Health ·(unknown), Shuo Chen, (unknown), Hsiang‐Kuang Chang, (unknown), (unknown), (unknown), (unknown), L-M Tseng, Hao‐Chien Wang, Lu Yang, (unknown)	2
20	The surgical treatment and prognostic factors of well-differentiated thyroid cancers in Chinese patients: a 20-year experience. 1996 ·PubMed ·L-M Tseng, (unknown), Hao‐Chien Wang, (unknown), (unknown), (unknown), (unknown), (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact